...
search icon
srzn-img

Surrozen Inc, Common Stock

SRZN

NAQ

$9.4767

+$0.08

(0.85%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$72.78M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
16.58K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.57
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.9 L
$18.17 H
$9.4767

About Surrozen Inc, Common Stock

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSRZNSectorS&P500
1-Week Return11.49%1.81%0.78%
1-Month Return31.62%3.75%2.88%
3-Month Return-20.33%-4.88%9.45%
6-Month Return-3.79%-2.96%-0.12%
1-Year Return-15.91%-6.25%11.31%
3-Year Return-73.38%12.43%61.11%
5-Year Return-93.75%39.86%96.65%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue--12.50M12.50M10.65M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":85.24,"profit":true}]
Cost of Revenue2.93M3.30M3.27M27.23M1.44M[{"date":"2020-12-31","value":10.76,"profit":true},{"date":"2021-12-31","value":12.11,"profit":true},{"date":"2022-12-31","value":12.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":5.3,"profit":true}]
Gross Profit(2.93M)(3.30M)12.50M(27.23M)9.21M[{"date":"2020-12-31","value":-23.43,"profit":false},{"date":"2021-12-31","value":-26.38,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-217.84,"profit":false},{"date":"2024-12-31","value":73.7,"profit":true}]
Gross Margin--100.00%(217.84%)86.47%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-217.84,"profit":false},{"date":"2024-12-31","value":86.47,"profit":true}]
Operating Expenses32.81M54.39M56.84M18.55M36.19M[{"date":"2020-12-31","value":57.72,"profit":true},{"date":"2021-12-31","value":95.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.64,"profit":true},{"date":"2024-12-31","value":63.68,"profit":true}]
Operating Income(32.81M)(54.39M)(44.34M)(45.78M)(25.54M)[{"date":"2020-12-31","value":-3280700000,"profit":false},{"date":"2021-12-31","value":-5439100000,"profit":false},{"date":"2022-12-31","value":-4433900000,"profit":false},{"date":"2023-12-31","value":-4578000000,"profit":false},{"date":"2024-12-31","value":-2553900000,"profit":false}]
Total Non-Operating Income/Expense182.00K(185.00K)9.12M5.04M(36.33M)[{"date":"2020-12-31","value":2,"profit":true},{"date":"2021-12-31","value":-2.03,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":55.32,"profit":true},{"date":"2024-12-31","value":-398.55,"profit":false}]
Pre-Tax Income(32.72M)(54.65M)(36.00M)(43.04M)(63.56M)[{"date":"2020-12-31","value":-3271600000,"profit":false},{"date":"2021-12-31","value":-5464800000,"profit":false},{"date":"2022-12-31","value":-3600400000,"profit":false},{"date":"2023-12-31","value":-4304200000,"profit":false},{"date":"2024-12-31","value":-6356400000,"profit":false}]
Income Taxes(91.00K)(2.14M)(8.34M)2.75M(63.56M)[{"date":"2020-12-31","value":-3.31,"profit":false},{"date":"2021-12-31","value":-77.69,"profit":false},{"date":"2022-12-31","value":-302.87,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-2309.74,"profit":false}]
Income After Taxes(32.63M)(52.51M)(27.67M)(45.79M)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(32.72M)(54.65M)(36.00M)(34.90M)(63.56M)[{"date":"2020-12-31","value":-3271600000,"profit":false},{"date":"2021-12-31","value":-5464800000,"profit":false},{"date":"2022-12-31","value":-3600400000,"profit":false},{"date":"2023-12-31","value":-3490400000,"profit":false},{"date":"2024-12-31","value":-6356400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(32.63M)(52.51M)(27.67M)(43.04M)(63.56M)[{"date":"2020-12-31","value":-3262500000,"profit":false},{"date":"2021-12-31","value":-5251000000,"profit":false},{"date":"2022-12-31","value":-2766900000,"profit":false},{"date":"2023-12-31","value":-4304200000,"profit":false},{"date":"2024-12-31","value":-6356400000,"profit":false}]
EPS (Diluted)-(1.80)(1.04)(5.54)(15.32)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-180,"profit":false},{"date":"2022-12-31","value":-104,"profit":false},{"date":"2023-12-31","value":-554,"profit":false},{"date":"2024-12-31","value":-1532,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SRZN
Cash Ratio 9.61
Current Ratio 10.02

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SRZN
ROA (LTM) -21.41%
ROE (LTM) -456.32%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SRZN
Debt Ratio Lower is generally better. Negative is bad. 0.95
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.05

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SRZN
Trailing PE NM
Forward PE NM
P/S (TTM) 6.62
P/B 13.58
Price/FCF NM
EV/R 2.73
EV/Ebitda 0.71

FAQs

What is Surrozen Inc share price today?

Surrozen Inc (SRZN) share price today is $9.4767

Can Indians buy Surrozen Inc shares?

Yes, Indians can buy shares of Surrozen Inc (SRZN) on Vested. To buy Surrozen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SRZN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Surrozen Inc be purchased?

Yes, you can purchase fractional shares of Surrozen Inc (SRZN) via the Vested app. You can start investing in Surrozen Inc (SRZN) with a minimum investment of $1.

How to invest in Surrozen Inc shares from India?

You can invest in shares of Surrozen Inc (SRZN) via Vested in three simple steps:

  • Click on Sign Up or Invest in SRZN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Surrozen Inc shares
What is Surrozen Inc 52-week high and low stock price?

The 52-week high price of Surrozen Inc (SRZN) is $18.17. The 52-week low price of Surrozen Inc (SRZN) is $5.9.

What is Surrozen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Surrozen Inc (SRZN) is 13.58

What is the Market Cap of Surrozen Inc?

The market capitalization of Surrozen Inc (SRZN) is $72.78M

What is Surrozen Inc’s stock symbol?

The stock symbol (or ticker) of Surrozen Inc is SRZN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top